<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features and diagnosis of Alzheimer disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features and diagnosis of Alzheimer disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features and diagnosis of Alzheimer disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Wolk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradford C Dickerson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 08, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H648249537"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alzheimer disease (AD) is a neurodegenerative disorder of uncertain cause and pathogenesis that primarily affects older adults and is the most common cause of dementia [<a href="#rid1">1</a>]. The most essential and often earliest clinical manifestation of AD is selective memory impairment, although there are exceptions. While treatments are available that can ameliorate some symptoms of the illness, there is no cure and the disease inevitably progresses in all patients. The first approval by the US Food and Drug Administration (FDA) of a therapy that is potentially disease-modifying provides a mandate for a specific diagnosis of AD in patients with cognitive impairment and dementia.</p><p>This topic reviews the clinical manifestations and diagnosis of AD. Other topics review the risk factors and treatment of AD:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a>.)</p><p></p><p>Other topics review the approach to patients with cognitive impairment and dementia and the clinical features of other dementia syndromes:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5085.html" rel="external">"Etiology, clinical manifestations, and diagnosis of vascular dementia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5070.html" rel="external">"Frontotemporal dementia: Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2086824550"><span class="h2">Age of onset</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical AD</strong> – AD is characteristically a disease of older age [<a href="#rid2">2</a>]. It is unusual for AD to occur before age 60. The incidence and prevalence of AD increase exponentially with age, essentially doubling in prevalence every 5 years after the age of 65 years. (See  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Incidence and prevalence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early-onset AD</strong> – Onset of symptoms before 65 years of age is uncommon, occurring in approximately five percent of patients with AD. Such patients often present for evaluation due to concerns about job performance. Many of these patients have no clear familial pattern and thus would be considered sporadic. Some exhibit familial clustering, but usually with affected family members being older at symptom onset.</p><p></p><p class="bulletIndent1">People with early-onset AD often present with symptoms somewhat atypical for this disease, such as language, visual, or mood-behavioral changes rather than predominant memory loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited forms of AD</strong> – These rare forms of AD routinely present before 65 years of age, and frequently in the fifth decade or earlier. These account for less than 1 percent of all cases of AD. They typically exhibit an autosomal-dominant inheritance pattern related to mutations in genes that alter beta-amyloid (Aβ) protein production or metabolism, including amyloid precursor protein (<em>APP</em>), presenilin-1 (<em>PSEN1</em>), and presenilin-2 (<em>PSEN2</em>).</p><p></p><p class="bulletIndent1">In a meta-analysis on 1307 patients with autosomal-dominant AD, the mean age of symptom onset was 46 years and was highly correlated with parental age of onset and mutation type [<a href="#rid3">3</a>]. Patients wi<em>th PSEN1</em> mutations had the earliest median age of onset (43 years)  (<a class="graphic graphic_figure graphicRef97086" href="/d/graphic/97086.html" rel="external">figure 1</a>). The range of symptom onset across all mutation types is nonetheless fairly broad, with some presentations in the fourth decade and some mutations not manifesting symptoms until the seventh decade (see  <a class="medical medical_review" href="/d/html/98647.html" rel="external">"Early-onset dementia in adults", section on 'Neurodegenerative dementias'</a>). If this is suspected, it is important to collect detailed information about family history to document a potential autosomal-dominant familial pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AD associated with Down syndrome</strong> – Individuals with Down syndrome have an additional gene dose of <em>APP</em> due to trisomy of chromosome 21 and inevitably develop AD pathology. Symptoms emerge at an earlier age, 10 to 20 years younger than the general population with AD [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Trisomy 21'</a>.)</p><p></p><p class="headingAnchor" id="H406197563"><span class="h2">Cardinal symptoms</span></p><p class="headingAnchor" id="H4"><span class="h3">Memory impairment</span><span class="headingEndMark"> — </span>Memory impairment is the most common initial symptom of AD dementia. Even when not the primary complaint, memory deficits can be elicited in most patients with AD at the time of presentation. Deficits in other cognitive domains may appear with or after the development of memory impairment.</p><p>The pattern of memory impairment in AD is distinctive [<a href="#rid5">5</a>]. Declarative episodic memory (memory of events occurring at a particular time and place) is usually profoundly affected in AD. This type of memory depends heavily on the hippocampus and other medial temporal lobe structures. By contrast, subcortical systems supporting procedural memory and motor learning are relatively spared until quite late in the disease. Memory for facts such as vocabulary and concepts (semantic memory) often becomes impaired somewhat later. Semantic memory is supported by neocortical temporal regions, particularly in the anterior temporal lobe. Subtler impairments of semantic memory may be a relatively early feature given early temporal lobe pathology [<a href="#rid6">6</a>].</p><p>Within episodic memory, there is a distinction between immediate recall (eg, mental rehearsal of a phone number), memory for recent events (which comes into play once material that has departed from consciousness must be recalled), and memory of more distant events (remote memory). Memory for recent events, served by the hippocampus, entorhinal cortex, and related structures in the medial temporal lobe, is prominently impaired in early AD [<a href="#rid7">7-9</a>]. By contrast, immediate memory (encoded in the sensory association and prefrontal cortices) is spared early on, as are memories that are consolidated for long periods of time (years), which can be recalled without hippocampal function.</p><p>The early memory deficit in AD is most precisely described as anterograde long-term episodic amnesia. Long-term memory can encompass time frames from less than a minute to years, but because the absolute time interval over which long-term memory can fail may actually be short (eg, inability to recall a few words after a couple minutes of distraction), patients and caregivers typically describe "short-term memory" problems. For this reason, we try to avoid the confusion afforded by the technical terms of long-term and short-term memory and use the term "recent memory impairment" to refer to the characteristic impairment.</p><p>Memory deficits develop insidiously and progress slowly over time, evolving to include deficits of semantic memory and immediate recall. Impairments of procedural memory appear only in late stages of AD.</p><p>Memory is usually tested by asking patients to learn and recall a series of words or objects immediately and then at a delay of 5 to 10 minutes. Impaired ability to recall objects with selective cues (hints) or recognize items as previously studied on a recognition memory test represents a more severe deficit and one that may be particularly specific for AD in its early presentation, as it reflects specific involvement of medial temporal lobe function [<a href="#rid10">10</a>]. Questions about orientation and recent current events are also useful memory tests. (See  <a class="medical medical_review" href="/d/html/14067.html" rel="external">"The mental status examination in adults", section on 'Memory'</a>.)</p><p>Clinicians should compare an informant's report with the patient's report of symptoms of memory loss in daily life, recognizing that many older individuals are unreliable reporters of their own memory impairment and can both overestimate and underestimate their deficits [<a href="#rid11">11</a>]. In addition, lack of insight may cause patients to deny or under-report their symptoms. It is critical to obtain the perspective of someone who knows the patient well.</p><p class="headingAnchor" id="H11"><span class="h3">Executive function and judgment/problem solving</span><span class="headingEndMark"> — </span>In early stages of AD, impairment in executive function may range from subtle to prominent [<a href="#rid12">12-14</a>]. In many cases, the patient underreports these symptoms, and an informant interview is critical. Family members and coworkers may find the patient less organized or less motivated; multitasking is often particularly compromised. As the disease progresses, an inability to complete tasks typically emerges. </p><p>Reduced insight into deficits (anosognosia) is a common but variable feature of AD [<a href="#rid15">15,16</a>]. It is common for patients to underestimate their deficits and offer alibis or explanations for them when they are pointed out. Interviewing an informant who has known the patient over time (usually a family member) is necessary; often it is the family member, not the patient, who brings the complaint of cognitive impairment to medical attention.</p><p>Loss of insight increases over time along with overall disease severity [<a href="#rid17">17</a>]. Such loss of insight may be associated with behavioral disturbances. Those with relatively preserved insight are more likely to be depressed; those with more impaired insight are likely to be agitated, be disinhibited, and exhibit psychotic features [<a href="#rid18">18,19</a>]. Lack of insight also may impact safety, as patients may attempt to take on tasks that they no longer have the capacity to perform effectively (eg, driving). (See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia", section on 'Driving'</a>.)</p><p class="headingAnchor" id="H1352148675"><span class="h3">Impairments in other cognitive domains</span><span class="headingEndMark"> — </span>Other cognitive domains become affected in patients with AD. Visuospatial impairments are often present relatively early, while deficits in language often manifest later in the disease course. These deficits develop and progress insidiously. Less commonly, language deficits, visuospatial abnormalities, or even executive functions may be impaired as the most prominent initial symptom [<a href="#rid12">12,13</a>]. (See <a class="local">'Atypical presentations'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">Behavioral and psychologic symptoms</span><span class="headingEndMark"> — </span>Neuropsychiatric symptoms are common in AD, particularly in the middle and late course of disease. These can begin with relatively subtle symptoms including apathy, social disengagement, and irritability. Apathy can be difficult to distinguish from depression, which can be difficult to diagnose in the setting of dementia, and the differences should be sought diligently because of treatment implications. In some cases empiric treatment of presumed depression is a reasonable management decision. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia", section on 'Depression'</a>.) </p><p>More problematic in patient management is the emergence of behavioral disturbances, including agitation, aggression, wandering, and psychosis (hallucinations, delusions, misidentification syndromes). A concomitant medical illness, medication toxicity, and other causes of delirium should be considered whenever new behavioral disturbances arise, especially if acute or subacute. The behavioral disturbances associated with AD are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Other signs and symptoms</span></p><p class="headingAnchor" id="H406197942"><span class="h3">Apraxia</span><span class="headingEndMark"> — </span>Dyspraxia, or difficulty performing learned motor tasks, usually occurs later in the disease after deficits in memory and language are apparent [<a href="#rid20">20</a>]. Before it is clinically manifest, dyspraxia can be elicited by asking the patient to perform ideomotor tasks, ie, pantomime the use of tools (eg, "show me how you would use a comb") [<a href="#rid21">21,22</a>]. Clinical dyspraxia leads to progressive difficulty first with complex, multistep motor activities, then with dressing, using utensils to eat, and other self-care tasks, and is a significant contributor to dependency in mid- to late stages of AD [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H406198009"><span class="h3">Olfactory dysfunction</span><span class="headingEndMark"> — </span>Changes in olfactory function are common in patients with AD and have been explored as a diagnostic tool. However, the predictive value of simple odor detection testing is limited [<a href="#rid24">24,25</a>], and the challenges of standardized assessment have limited widespread use of olfactory assessment [<a href="#rid26">26,27</a>]. Furthermore, olfactory dysfunction is not a clinical symptom that is often noted by patients or their families. That said, it may enhance classification of patients beyond cognitive measures alone [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2086824403"><span class="h3">Sleep disturbances</span><span class="headingEndMark"> — </span>Sleep disturbances are common in patients with AD [<a href="#rid29">29</a>]. Patients with AD spend more time in bed awake and have more fragmented sleep compared with older adults without AD. Such changes may occur very early in the disease process, including in patients who are cognitively normal but have biomarker evidence of Aβ deposition [<a href="#rid30">30-32</a>]. (See  <a class="medical medical_review" href="/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Sleep changes in aging and dementia'</a>.) </p><p class="headingAnchor" id="H406198116"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Seizures occur in 10 to 20 percent of patients with AD, usually in the later stages of disease [<a href="#rid33">33-37</a>]. Younger patients, including those with autosomal-dominant forms of AD, may be at higher risk for seizures, which may occur early in the course of disease [<a href="#rid38">38,39</a>].</p><p>The predominant seizure type is focal nonmotor with impaired awareness, with symptoms often suggestive of medial temporal lobe onset (eg, amnestic spells, unexplained emotions, metallic taste, rising epigastric sensation) [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/2223.html" rel="external">"Seizures and epilepsy in older adults: Etiology, clinical presentation, and diagnosis", section on 'Epilepsy (unprovoked seizures)'</a>.)</p><p class="headingAnchor" id="H406204553"><span class="h3">Motor signs</span><span class="headingEndMark"> — </span>In the early stages, patients with AD generally have a normal neurologic examination except for the cognitive examination. While pyramidal and extrapyramidal motor signs, myoclonus, and seizures do occur in patients with AD, these are typically late-stage findings [<a href="#rid40">40</a>]. If these are clinically apparent in early to middle stages, alternative diagnoses should be considered [<a href="#rid41">41</a>].</p><p>Myoclonus may emerge in some patients with AD, typically those with more rapid than usual decline. Similarly, primitive reflexes (grasp, snout reflexes, gegenhalten) and incontinence are late, rather than early, features of AD. </p><p class="headingAnchor" id="H14"><span class="h2">Atypical presentations</span><span class="headingEndMark"> — </span>A minority of patients with AD do not present in the classic fashion with progressive amnestic dementia [<a href="#rid42">42,43</a>]. Distinguishing these cases from other causes of dementia can be challenging. Neuropathologic studies in such patients have found Alzheimer pathology with an atypical neuroanatomic distribution (particularly neurofibrillary tangles) that corresponds with the anatomy of the most prominent clinical deficits; neuroimaging studies often have corresponding findings [<a href="#rid43">43-48</a>]. Some case series suggest that these atypical forms are more common in early-onset presentations (before 65 years of age) in patients who do not carry one of the autosomal-dominant familial mutations [<a href="#rid49">49,50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posterior cortical atrophy</strong> – This syndrome manifests with progressive cortical visual impairment [<a href="#rid42">42,46,51-56</a>]. Patients are often first evaluated by optometrists or ophthalmologists for visual complaints, such as difficulty reading and driving [<a href="#rid43">43,54</a>]. A proposed consensus classification framework requires three or more of the following early or presenting features [<a href="#rid57">57</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Space perception deficit</p><p class="bulletIndent2"><span class="glyph">•</span>Simultanagnosia (ie, the inability to integrate a visual scene despite adequate visual acuity to resolve individual elements)</p><p class="bulletIndent2"><span class="glyph">•</span>Object perception deficit</p><p class="bulletIndent2"><span class="glyph">•</span>Constructional dyspraxia</p><p class="bulletIndent2"><span class="glyph">•</span>Environmental agnosia</p><p class="bulletIndent2"><span class="glyph">•</span>Oculomotor apraxia (the inability to direct gaze accurately to a new target)</p><p class="bulletIndent2"><span class="glyph">•</span>Dressing apraxia</p><p class="bulletIndent2"><span class="glyph">•</span>Optic ataxia (the inability to reach accurately under visual guidance)</p><p class="bulletIndent2"><span class="glyph">•</span>Alexia</p><p class="bulletIndent2"><span class="glyph">•</span>Left/right disorientation</p><p class="bulletIndent2"><span class="glyph">•</span>Acalculia</p><p class="bulletIndent2"><span class="glyph">•</span>Limb apraxia</p><p class="bulletIndent2"><span class="glyph">•</span>Apperceptive prosopagnosia</p><p class="bulletIndent2"><span class="glyph">•</span>Agraphia</p><p class="bulletIndent2"><span class="glyph">•</span>Homonymous visual field defect</p><p class="bulletIndent2"><span class="glyph">•</span>Finger agnosia</p><p></p><p class="bulletIndent1">In addition, there should be relative sparing of anterograde memory function, speech and nonvisual language functions, executive functions, and behavior and personality. Neuroimaging usually shows predominant occipitoparietal or occipitotemporal atrophy, hypometabolism, or hypoperfusion [<a href="#rid45">45,57-60</a>].</p><p></p><p class="bulletIndent1">Some patients with a biparietal variant present with dyspraxia and have difficulty completing simple bimanual tasks, such as dressing [<a href="#rid42">42,61</a>]. Other early clinical features can include visuospatial disorientation, dysgraphia, and language impairment with semantic memory deficits (see <a class="local">'Memory impairment'</a> above). Neuropathologic examination and neuroimaging studies demonstrate prominent involvement of the parietal lobes bilaterally.</p><p></p><p class="bulletIndent1">In most patients, neuropathologic examination reveals Alzheimer pathology with a greater predominance of pathology involving visual association areas and even primary visual cortex compared with more typical presentations [<a href="#rid43">43,55,59,62</a>]. A minority of patients with this syndrome have alternative pathologies, such as dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), prion disease, or frontotemporal lobar degeneration (FTLD) [<a href="#rid55">55,59,63,64</a>]. In such patients, other core features of the respective diseases are usually present (eg, fluctuating cognition, recurrent visual hallucinations, and parkinsonism in DLB; limb rigidity, akinesia, dystonia, or myoclonus in CBD) [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a> and  <a class="medical medical_review" href="/d/html/14135.html" rel="external">"Corticobasal degeneration", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions"</a> and  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary progressive aphasia</strong> – Primary progressive aphasia (PPA) refers to a clinically and pathologically heterogeneous group of neurodegenerative disorders characterized by progressive language difficulty with relative sparing of memory and other cognitive functions, at least early in the disease course. Based on the type of language impairment, PPA is further subclassified into three variants: nonfluent, semantic, or logopenic. PPA is usually associated with FTLD rather than Alzheimer pathology. However, a significant percentage (up to one-third) are found at autopsy to have AD instead [<a href="#rid42">42,43,45,65-67</a>]. The clinical variant of PPA most likely to be due to AD is the logopenic variant, characterized by frequent word-finding pauses and paraphasic speech errors without major grammar or comprehension deficits [<a href="#rid45">45,67-71</a>]. AD pathology is also sometimes found in patients with nonfluent or semantic variants of PPA, but this is less common [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/d/html/5070.html" rel="external">"Frontotemporal dementia: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">In patients with logopenic variant PPA, structural imaging often shows predominant left posterior perisylvian or parietal atrophy [<a href="#rid72">72</a>]. 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) and single-photon emission computed tomography (SPECT) may highlight hypometabolism or hypoperfusion in the same areas. Elevated signal with amyloid PET imaging suggests a role for AD pathology and is seen in approximately 85 percent of logopenic variant cases and in approximately 20 percent of semantic and nonfluent variants in one series [<a href="#rid73">73</a>], but some cases have mixed pathologies [<a href="#rid74">74</a>], so amyloid PET should not be viewed as diagnostic of AD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysexecutive or "frontal" variant</strong> – A subset of patients with AD present with prominent deficits in executive function relative to amnesia. In one case series of 88 such patients, magnetic resonance imaging (MRI) revealed more thinning in the frontoparietal cortical regions, the clinical course appeared to involve more rapid progression, and the prevalence of the apolipoprotein E (<em>APOE)</em> ε4 allele was lower compared with the more typical AD patients with prominent memory deficits [<a href="#rid75">75,76</a>].</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Mixed dementias</span><span class="headingEndMark"> — </span>It is common for Alzheimer pathology to coexist with other processes, including vascular lesions, cortical Lewy bodies, TAR DNA binding protein 43 (TDP-43) deposits, argyrophilic grain disease, and Parkinson disease. The combination of two pathologies can influence the clinical presentation and course of the disease and present diagnostic challenges [<a href="#rid77">77</a>]. In general, these additional pathologies result in greater likelihood of dementia and faster than usual rate of decline [<a href="#rid78">78-80</a>].</p><p>As expected, the most common combination is that of AD and vascular dementia. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5085.html" rel="external">"Etiology, clinical manifestations, and diagnosis of vascular dementia"</a>.)</p><p>Another combination that is described is that of diffuse Lewy body and AD dementia [<a href="#rid81">81-83</a>]. In affected patients, prominent memory loss can coexist with one or more features of DLB, including visual hallucinations, fluctuations in sensorium, parkinsonism, and falls. (See  <a class="medical medical_review" href="/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>AD progresses inexorably. The progress of the disease can be measured with mental status scales such as the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the clinical dementia rating (CDR) scale, and/or an instrument measuring independent daily function such as the Functional Activities Questionnaire  (<a class="graphic graphic_table graphicRef53706" href="/d/graphic/53706.html" rel="external">table 1</a>). While the clinical course as measured by such scales is not necessarily linear, a number of studies have found that patients decline 3 to 3.5 points on average on the MMSE each year [<a href="#rid84">84-87</a>], with a minority (&lt;10 percent) having a more rapidly progressive decline of 5 to 6 points on annual MMSE [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/14058.html" rel="external">"Mental status scales to evaluate cognition", section on 'Longitudinal assessment'</a>.)</p><p>An older age of onset of AD (&gt;80 years) may be associated with a slower rate of decline compared with younger patients [<a href="#rid89">89</a>]. Conversely, early neuropsychiatric symptoms including psychosis, agitation, and aggression have been associated with more rapid decline [<a href="#rid90">90</a>].</p><p>The average life expectancy after a diagnosis of AD has been reported to be between 8 and 10 years but may range from 3 to 20 years, and it depends heavily on how impaired the person is at the time of diagnosis [<a href="#rid91">91-94</a>]. Survival also relates to age at onset of symptoms. Patients generally succumb to terminal-stage complications that relate to advanced debilitation, such as dehydration, malnutrition, and infection. (See  <a class="medical medical_review" href="/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a>.)</p><p class="headingAnchor" id="H406198475"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H23"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>AD should be suspected in any older adult with insidious onset, progressive decline in memory, and at least one other cognitive domain leading to impaired functioning. Thus, a detailed cognitive and general neurologic examination is paramount. Clinicians should also consider potential contributors to the dementia syndrome such as adverse effects of medication, depression, and metabolic disorders and deficiencies. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Evaluation'</a>.)</p><p>Many clinicians make use of standardized mental status scales to document the presence and progression of dementia. The Montreal Cognitive Assessment (MoCA) [<a href="#rid95">95,96</a>] is our preferred brief assessment tool because it has better sensitivity for executive and language dysfunction compared with other brief tests such as the Mini-Mental State Examination (MMSE). The typical cutoff score for normal performance on the MoCA is 26 (ie, 25 and below is considered abnormal). Cutoffs should be adjusted based on appropriate norms, including education adjustment [<a href="#rid97">97</a>]. The MoCA is available online and in several languages at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mocatest.org%2F&amp;token=kKXHxK%2Bt2cji8cnnyYI7JCchZWPNKNaVKXzsuLn2DQHM3rPg7ASjaAVV8wj9164d&amp;TOPIC_ID=5071" target="_blank">www.mocatest.org</a>. (See  <a class="medical medical_review" href="/d/html/14058.html" rel="external">"Mental status scales to evaluate cognition", section on 'Montreal Cognitive Assessment (MoCA)'</a>.)</p><p>The diagnosis of dementia cannot be made simply on the basis of a low score on one of these tests; the most important part of the diagnostic evaluation is a detailed history including the perspective of an informant (eg, spouse or adult child), interviewed separately from the patient if possible. The use of validated questionnaires to document the preservation or loss of independent function, as well as the presence or types of neuropsychiatric symptoms, is also an important part of the evaluation. Validated questionnaires to measure cognitive symptoms also can be helpful [<a href="#rid98">98</a>]. Additional detail on these instruments is presented separately. (See  <a class="medical medical_review" href="/d/html/14058.html" rel="external">"Mental status scales to evaluate cognition"</a>.)</p><p class="headingAnchor" id="H406204628"><span class="h2">Role of neuropsychologic testing</span><span class="headingEndMark"> — </span>Formal neuropsychologic assessment can be helpful in the evaluation of individuals with cognitive impairment and dementia. Cognitive testing under standardized conditions using demographically appropriate norms is more sensitive to the presence of impairments, especially impairments of executive function. Neuropsychologic assessment can be useful in a variety of settings:</p><p class="bulletIndent1"><span class="glyph">●</span>To establish a baseline in order to follow the patient over time. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Neuropsychological testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To help differentiate among different forms of neurodegenerative dementias or between a neurodegenerative dementia and other etiologies of cognitive impairment, such as cerebrovascular disease or depression. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Neuropsychological testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To assess competencies and guide recommendations pertaining to driving, financial decisions, and need for increasing supervision. (See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To identify opportunities for compensatory or rehabilitative treatment strategies. (See  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia", section on 'Rehabilitation'</a>.)</p><p></p><p class="headingAnchor" id="H406199175"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Brain imaging, preferably with magnetic resonance imaging (MRI), is indicated in the evaluation of patients with suspected AD [<a href="#rid99">99</a>]. Brain MRI can document potential alternative or additional diagnoses including cerebrovascular disease, other structural diseases (chronic subdural hematoma, cerebral neoplasm, normal pressure hydrocephalus), and regional brain atrophy suggesting frontotemporal dementia (FTD) or other types of neurodegenerative disease. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Neuroimaging'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – Structural MRI findings in AD include both generalized and focal atrophy, as well as white matter lesions. In general, these findings are nonspecific.</p><p></p><p class="bulletIndent1">The most characteristic focal finding in AD is reduced hippocampal volume or medial temporal lobe atrophy [<a href="#rid47">47,100-103</a>]. Because hippocampal volumes decline in normal aging, however, age-specific criteria are needed [<a href="#rid100">100,101,104</a>]. The finding of hippocampal atrophy provides incremental support for a diagnosis of AD in a patient with a typical clinical presentation, but it is not sufficiently specific to contribute significantly to the accuracy of the diagnosis over the clinical assessment alone [<a href="#rid105">105</a>]. Some studies have suggested that MRI features may predict rate of decline of AD and in the future may guide treatment decisions [<a href="#rid85">85,106</a>]. Hippocampal volumetry using age-corrected norms available from the Alzheimer Disease Neuroimaging Initiative can predict rates of progression of mild cognitive impairment (MCI) to dementia [<a href="#rid107">107</a>]. However, the tools to generate these measurements are not in wide use, nor have these findings been validated in a clinical practice setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FDG-PET and SPECT</strong> – Functional brain imaging with 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) or single-photon emission computed tomography (SPECT) reveals distinct regions of hypometabolism (PET) and hypoperfusion (SPECT) in AD. These areas include the hippocampus, the precuneus (mesial parietal lobes), and the lateral parietal and posterior temporal cortex [<a href="#rid9">9,108-113</a>]. In practice, FDG-PET may be most useful in distinguishing AD from FTD in patients with atypical presentations [<a href="#rid114">114-117</a>], as well as discriminating from non-neurodegenerative conditions, such as depression. FDG-PET and SPECT are the only functional neuroimaging methods that are currently reasonably widely available for clinical use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amyloid PET imaging</strong> – Amyloid PET tracers (<a class="drug drug_general" data-topicid="83331" href="/d/drug information/83331.html" rel="external">florbetapir F-18</a>, <a class="drug drug_general" data-topicid="91387" href="/d/drug information/91387.html" rel="external">flutemetamol F-18</a>, <a class="drug drug_general" data-topicid="94523" href="/d/drug information/94523.html" rel="external">florbetaben F-18</a>) measure amyloid lesion burden in the brain; these aid in the diagnosis of AD, differentiating AD from other causes of dementia [<a href="#rid117">117-140</a>]. A large study of the use of amyloid PET imaging in clinical decision-making was completed in December 2017 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02420756&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOazJjgVrkUUHIYn%2FNPwCY76Br9iQ%2FcF9y1CC%2Bjt3PZjg%3D%3D&amp;TOPIC_ID=5071" target="_blank">NCT02420756</a>) and revealed that an amyloid PET result significantly impacted clinical management and etiologic diagnosis [<a href="#rid141">141</a>]. At present, these scans are generally not covered by most health insurances plans in the United States.</p><p></p><p class="bulletIndent1">These tracers have been approved by regulatory agencies in the United States and elsewhere as qualitative assessments of beta-amyloid (Aβ) plaque density [<a href="#rid142">142,143</a>]. Since there are issues with how much ligand binding to plaques constitutes a "positive" scan, the US Food and Drug Administration (FDA) approval specifies that an amyloid PET scan that is negative decreases the likelihood that a patient with dementia has AD. In a symptomatic dementia patient, a positive scan indicates that the person has amyloid plaque pathology, but such a finding does not rule out a coexisting pathology. Based on the FDA approval label, scans are determined positive or negative based on a radiologist's clinical read, although there are more quantitative approaches that are used in research and may complement such clinical assessments.</p><p></p><p class="bulletIndent1">A consensus opinion of the Amyloid Imaging Task Force, the Society of Nuclear Medicine, and the Alzheimer's Association concluded that amyloid imaging is not appropriate in patients who meet the core clinical criteria for probable AD and have a typical age of onset, and such a scan should not be used to determine dementia severity [<a href="#rid144">144</a>]. These guidelines may be adjusted with the approval of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>, for which a positive amyloid scan is generally believed to be a prerequisite [<a href="#rid145">145</a>]. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Aducanumab'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tau PET imaging</strong> – A number of tau PET imaging tracers have been in development and hold potential as markers of the tauopathy of AD. A number of studies have demonstrated that these tracers better track disease progression and more highly associate with patterns of atrophy and clinical features than amyloid PET does [<a href="#rid146">146,147</a>].</p><p></p><p class="bulletIndent1">One such tracer, <a class="drug drug_general" data-topicid="128354" href="/d/drug information/128354.html" rel="external">flortaucipir F-18</a>, was approved by the FDA for determining the burden of neurofibrillary tangles in individuals being evaluated for AD; this tracer is not useful for measuring non-AD tauopathies such as frontotemporal lobar degeneration (FTLD) [<a href="#rid148">148,149</a>]. As with amyloid PET, there is limited insurance coverage of this agent.</p><p></p><p class="headingAnchor" id="H406207357"><span class="h2">Role of biomarkers</span><span class="headingEndMark"> — </span>There are several widely investigated biomarkers for the molecular and degenerative process of AD that can be supportive of a diagnosis of AD but are not yet recommended for routine diagnostic purposes  (<a class="graphic graphic_table graphicRef97451" href="/d/graphic/97451.html" rel="external">table 2</a>) [<a href="#rid12">12</a>]. Such testing can add incremental confidence to a clinical diagnosis of AD, however, and can be useful in certain circumstances, including early-onset dementia and atypical presentations of AD in which the differential diagnosis includes other non-amyloid neurodegenerative diseases such as FTD. Evidence of the presence of amyloid is also likely to guide initiation of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>, which specifically targets this protein. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Aducanumab'</a>.)</p><p>Molecular biomarkers of Aβ protein deposition include:</p><p class="bulletIndent1"><span class="glyph">●</span>Low cerebrospinal fluid (CSF) Aβ42<sub> </sub>(or Aβ42:Aβ40 ratio)</p><p class="bulletIndent1"><span class="glyph">●</span>Positive amyloid PET imaging using one of the amyloid PET tracers</p><p></p><p>Appropriate use guidance states that one of these tests should be positive in patients who are treated with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Aducanumab'</a>.) </p><p>Biomarkers of tau deposition (a key component of neurofibrillary tangles) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased CSF total tau and phospho-tau</p><p class="bulletIndent1"><span class="glyph">●</span>Tau PET imaging using <a class="drug drug_general" data-topicid="128354" href="/d/drug information/128354.html" rel="external">flortaucipir F-18</a></p><p></p><p>In addition to these molecular biomarkers, there are several topographic or neurodegenerative biomarkers used to assess the downstream brain changes that correlate with the regional distribution of neuronal dysfunction and eventual neuronal death associated with AD [<a href="#rid150">150</a>]. These include medial temporal lobe atrophy on MRI and reduced glucose metabolism in the temporoparietal regions on FDG-PET. (See <a class="local">'Neuroimaging'</a> above.)</p><p>In general, the topographic biomarkers are less specific than the molecular biomarkers but correlate better with the emergence of clinical symptoms. None of these tests is valid as a standalone diagnostic test and their combination may best predict outcomes [<a href="#rid151">151</a>]. Research criteria have begun to incorporate these biomarkers in the definition of AD with the goal of providing a biologically based diagnosis rather than a purely clinical diagnosis [<a href="#rid152">152</a>]. These criteria define AD based on the presence of Aβ and tau biomarkers and are irrespective of the patient's clinical impairments. Markers of neurodegeneration also provide information about disease staging, and, taken together, this has been referred to as the amyloid, tau, and neurodegeneration (ATN) framework.</p><p>Plasma biomarkers show promise but do not currently have an established role in clinical practice; more studies are needed [<a href="#rid153">153-156</a>]. Decreased APOE and APOE ε4 plasma levels as well as a variety of other plasma/serum and CSF proteins have been assessed for predictive value for AD in persons without dementia and in patients with MCI [<a href="#rid157">157-160</a>]. Ongoing research is investigating the role of such biomarkers that may help distinguish AD from other forms of dementia [<a href="#rid161">161,162</a>]. In particular, measures of plasma phospho-tau<sub>181</sub> and phospho-tau<sub>217</sub> have demonstrated strong correlation with CSF phospho-tau measures and association with amyloid and tau PET imaging [<a href="#rid161">161-163</a>]. Similarly, a plasma measure of β42/β40 using an immunoprecipitation and liquid chromatography-mass spectrometry assay has shown promise in detection of amyloid [<a href="#rid164">164</a>] and can be commercially ordered, although it is not currently covered by insurance payers in the United States. </p><p>Studies of these and other emerging plasma/serum and CSF biomarkers for AD in the assessment of prognosis are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'CSF biomarkers'</a> and  <a class="medical medical_review" href="/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Plasma biomarkers'</a>.)</p><p class="headingAnchor" id="H406199181"><span class="h2">Other laboratory testing</span><span class="headingEndMark"> — </span>Routine laboratory tests are not useful in the positive diagnosis of AD; however, some laboratory tests are indicated to exclude contributing secondary causes or conditions that may exacerbate cognitive impairment. (See  <a class="medical medical_review" href="/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Laboratory testing'</a>.)</p><p class="headingAnchor" id="H1583868274"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is not recommended in the routine evaluation of patients with AD. <em>APOE</em> genotyping adds marginally to the predictive value of clinical criteria for AD and may stratify risk of progression of amnesic MCI to AD, but both false positives and negatives occur [<a href="#rid165">165,166</a>].</p><p>Genetic testing for <em>APP</em>, <em>PSEN1</em>, and <em>PSEN2</em> mutations is commercially available but should be reserved for cases in which young-onset dementia occurs in the setting of a family history positive for an autosomal-dominant distribution of early-onset cases. This should not be performed in asymptomatic family members or patients without appropriate professional genetic counseling, since there would be implications for family members as well as the patient. (See  <a class="medical medical_review" href="/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Genetic testing'</a>.)</p><p class="headingAnchor" id="H406198512"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A detailed clinical assessment provides reasonable diagnostic accuracy for AD in the majority of patients, although sensitivity and specificity in particular are limited [<a href="#rid12">12</a>]. That said, misdiagnosis is almost always another neurodegenerative or nonreversible cause. The clinical criteria for AD include a history of insidious onset and progressive course of cognitive decline, exclusion of other etiologies, and documentation of cognitive impairments in one or more domains. </p><p>Definitive diagnosis of AD requires histopathologic examination, which is rarely done in life [<a href="#rid167">167-169</a>]. The diagnosis of AD in practice depends on the clinical criteria outlined below. </p><p class="headingAnchor" id="H24"><span class="h2">Alzheimer disease dementia</span><span class="headingEndMark"> — </span>Criteria for the diagnosis of probable AD dementia have been established by the National Institute on Aging and the Alzheimer's Association (NIA-AA) and most recently updated in 2011 [<a href="#rid12">12,41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NIA-AA criteria for probable AD dementia</strong> require the presence of dementia <strong>and</strong> the following characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interference with ability to function at work or at usual activities</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A decline from a previous level of functioning and performing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Not explained by delirium or major psychiatric disorder</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment established by history-taking from the patient <strong>and</strong> a knowledgeable informant; and objective bedside mental status examination or neuropsychologic testing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment involving a minimum of two of the following domains:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Impaired ability to acquire and remember new information</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Impaired reasoning and handing of complex tasks, poor judgment</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Impaired visuospatial abilities</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Impaired language functions</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Changes in personality, behavior, or comportment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other core clinical criteria include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Insidious onset</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clear-cut history of worsening</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Initial and most prominent cognitive deficits are one of the following: amnestic presentation (ie, impairment in learning and recall of recently learned information) <strong>or</strong> nonamnestic presentations (including either a language presentation, with prominent word-finding deficits; a visuospatial presentation, with visual cognitive deficits; or a dysexecutive presentation, with prominent impairment of reasoning, judgment, and/or problem solving)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No evidence of substantial concomitant cerebrovascular disease, core features of dementia with Lewy bodies (DLB), prominent features of behavioral variant frontotemporal dementia (FTD) or prominent features of semantic or nonfluent/agrammatic variants of primary progressive aphasia (PPA), or evidence of another concurrent, active neurologic or non-neurologic disease or use of medication that could have a substantial effect on cognition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NIA-AA criteria for possible AD dementia</strong> include either of the following clinical scenarios [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atypical course – The core clinical criteria above are met in terms of the nature of the cognitive deficits, but there is either a sudden onset of cognitive impairment or insufficient historical detail or objective documentation of progressive decline.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Etiologically mixed presentation – All of the core clinical criteria for AD dementia are met, but the individual also has evidence of concomitant cerebrovascular disease, features of DLB other than the dementia itself, or evidence for another neurologic or medical comorbidity or medication that could have a substantial effect on cognition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for AD</strong> are also commonly used. Criteria for AD were revised in 2013  (<a class="graphic graphic_table graphicRef91288" href="/d/graphic/91288.html" rel="external">table 3</a>) [<a href="#rid170">170</a>]. The DSM-5 definition of probable AD (now called major neurocognitive disorder due to AD) differs from prior versions in that the cognitive domains have been renamed and expanded to include learning and memory, language, executive function, complex attention, perceptual-motor, and social cognition. Previously, the criteria recognized five domains (memory, aphasia, apraxia, agnosia, and executive function). Like prior versions, the criteria continue to require both memory impairment and evidence of decline in at least one other cognitive domain. New to the criteria is the recognition of genetic testing results, if known, as supportive of a diagnosis of probable AD.</p><p></p><p class="bulletIndent1">While less substantially validated compared with the NIA-AA criteria, the DSM-IV criteria appeared to have similar accuracy [<a href="#rid99">99,171</a>]. The performance characteristics of the DSM-5 criteria compared with the DSM-IV and NIA-AA criteria are not yet known.</p><p></p><p class="headingAnchor" id="H406204394"><span class="h2">MCI due to Alzheimer disease</span><span class="headingEndMark"> — </span>Amnestic mild cognitive impairment (MCI) refers to a state of circumscribed anterograde long-term memory impairment with preserved general cognitive and social functioning [<a href="#rid172">172</a>]. Amnestic MCI frequently represents an early stage of AD, with a progression rate to dementia at approximately 10 to 15 percent per year [<a href="#rid172">172,173</a>]. Nonamnestic MCI, in which cognitive domains outside of memory are affected, is less frequently associated with prodromal AD but may be in a significant minority of patients. (See  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment", section on 'Amnestic MCI'</a> and  <a class="medical medical_review" href="/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Progression to dementia'</a>.)</p><p>Formal clinical diagnostic criteria for MCI due to AD have been developed by a panel convened by the NIA-AA [<a href="#rid174">174</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>A concern regarding cognition reported by the patient or informant or observed by the clinician</p><p class="bulletIndent1"><span class="glyph">●</span>Objective evidence of impairment in one or more cognitive domains that is not explained by age or education</p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of independence in functional abilities</p><p class="bulletIndent1"><span class="glyph">●</span>Impairments do not meet criteria for dementia</p><p></p><p>MCI may occur as a prodrome to several neurodegenerative dementias, as well as non-neurodegenerative conditions (eg, depression, medicine effects). Therefore, the specific designation of MCI due to AD is used when a biomarker associated with AD (eg, cerebrospinal fluid [CSF] testing of beta-amyloid [Aβ], tau, and phospho-tau; amyloid imaging; or functional scan consistent with AD) is present in the affected subject  (<a class="graphic graphic_table graphicRef97451" href="/d/graphic/97451.html" rel="external">table 2</a>). Using the NIA-AA criteria on a cohort of research subjects with MCI, individuals with cognitive impairment and both amyloid and neuronal injury biomarkers had an approximately 60 percent progression rate to AD dementia over three years [<a href="#rid175">175</a>]. By contrast, individuals with amnestic MCI and both negative amyloid and neuronal injury markers have a low progression rate: 12 percent over three years in one study [<a href="#rid176">176</a>].</p><p>The International Working Group (IWG) recognizes a similar clinical presentation that, when accompanied by biomarker evidence of AD, is referred to as prodromal AD [<a href="#rid150">150,177</a>]. The designation of prodromal AD has been associated with similar progression rates compared with the NIA-AA criteria [<a href="#rid175">175</a>].</p><p class="headingAnchor" id="H406204401"><span class="h2">Preclinical Alzheimer disease</span><span class="headingEndMark"> — </span>Preclinical AD refers to the stage of AD in which the molecular pathology of AD is already present in the brain but is not yet clinically expressed. Individuals are by definition asymptomatic and cognitively normal. Preclinical AD is defined by biomarker measures and is only recommended for use in research, in the context of clinical trials for early intervention strategies and the longitudinal study of people at risk. According to the IWG, preclinical AD encompasses two groups [<a href="#rid178">178</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic at risk for AD refers to cognitively normal individuals with evidence of AD molecular pathology by laboratory or imaging biomarkers. It is not currently known whether progression to symptomatic AD is inevitable in such individuals. Autopsy data revealing that people may die with normal cognition and pathologic changes of AD sufficient to make a diagnosis suggest that symptomatic AD will not occur in every subject with amyloid in the brain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presymptomatic AD also refers to cognitively normal and asymptomatic carriers of a dominantly inherited gene mutation that causes AD. Symptoms of AD will almost certainly develop in these individuals over a normal lifespan. (See  <a class="medical medical_review" href="/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Early-onset Alzheimer disease'</a>.)</p><p></p><p>The NIA-AA framework proposes three stages of preclinical AD, recognizing that some individuals will not progress beyond stage 1 or stage 2, and that individuals in stage 3 are probably most likely to progress to MCI and AD dementia  (<a class="graphic graphic_figure graphicRef97452" href="/d/graphic/97452.html" rel="external">figure 2</a>) [<a href="#rid179">179</a>]. As described above, a subsequent NIA-AA research framework was published in 2018 that further explicates the continuum of AD, with the disease being defined by amyloid, tau, and neurodegeneration (ATN) biomarkers in the context of the clinical stages from preclinical to MCI to dementia stages [<a href="#rid152">152</a>]. These are research criteria that have not yet been validated through longitudinal studies, and they are not currently recommended for use outside a research setting. </p><p class="headingAnchor" id="H406198381"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The most common disorders considered in the differential diagnosis of AD are vascular dementia and other neurodegenerative dementias. The two most common neurodegenerative dementias after AD are dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). </p><p class="bulletIndent1"><span class="glyph">●</span>Vascular dementia is caused by either ischemic or hemorrhagic strokes or small vessel cerebrovascular disease. Diagnosis is most specific if there is a stroke-like course of illness, neurologic signs of stroke on examination, and imaging evidence of cerebrovascular disease. However, the course of illness may appear smoothly progressive, and there may be no elementary neurologic signs. Cerebrovascular disease commonly co-occurs with AD. With increasing age, it is more common than not to find both AD and cerebrovascular disease in the brain of a patient with dementia. (See  <a class="medical medical_review" href="/d/html/5085.html" rel="external">"Etiology, clinical manifestations, and diagnosis of vascular dementia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLB may be the second most common type of degenerative dementia after AD. Clinical features that help distinguish this from AD include prominent early appearance of visual hallucinations, along with parkinsonism, cognitive fluctuations, dysautonomia, rapid eye movement (REM) sleep behavior disorder, and neuroleptic sensitivity. (See  <a class="medical medical_review" href="/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FTD is a neuropathologically and clinically heterogeneous disorder characterized by focal degeneration of the frontal and/or temporal lobes. Early alteration of personality, social and emotional behavior, and executive functioning are prominent clinical characteristics of behavioral variant FTD. Primary progressive aphasia (PPA) is a form of FTD in which gradually progressive language impairment is the core feature early in the course. There are three major subtypes, with the semantic and nonfluent variants being associated usually with frontotemporal lobar degeneration (FTLD) pathologies (usually tau or TDP-43). PPA, particularly the logopenic variant, can also be a presentation of AD. (See  <a class="medical medical_review" href="/d/html/5070.html" rel="external">"Frontotemporal dementia: Clinical features and diagnosis"</a> and <a class="local">'Atypical presentations'</a> above.)</p><p></p><p class="headingAnchor" id="H3381963271"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15523.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16421.html" rel="external">"Patient education: Caring for someone with Alzheimer disease or dementia (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16836.html" rel="external">"Patient education: Evaluating memory and thinking problems (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age at onset</strong> – Alzheimer disease (AD) is usually a disease of older age. The incidence increases exponentially with age over 65 years.</p><p></p><p class="bulletIndent1">Early-onset (onset of symptoms in a person younger than 65) AD is unusual, and in some but not all cases is familial. Familial early-onset AD makes up less than 1 percent of cases (several hundred families around the world) and often follows an autosomal-dominant pattern of inheritance. (See <a class="local">'Age of onset'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cognitive deficits</strong> – These appear and progress insidiously. Memory impairment, specifically loss of memory of recent events, is the most frequent feature of AD and is usually its first manifestation. Other cognitive deficits appear with or after the development of memory impairment. Executive dysfunction and impaired visuospatial skills tend to be affected early, while deficits in language function and behavioral symptoms often manifest later. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuropsychiatric and behavioral symptoms</strong> – These are common in middle and late stages of AD but may occur early in the course in some patients. (See <a class="local">'Behavioral and psychologic symptoms'</a> above and  <a class="medical medical_review" href="/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noncognitive neurologic deficits</strong> – Pyramidal and extrapyramidal motor signs, myoclonus, and seizures can occur in late stages of AD but are uncommon in early and middle stages. (See <a class="local">'Other signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atypical presentations</strong> – These include a visual variant (posterior cortical atrophy), a variant with progressive aphasia, and a variant with progressive executive dysfunction as the predominant symptom. Atypical presentations are more common in younger people with AD. (See <a class="local">'Atypical presentations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – AD is inexorably progressive, but the rate of progression can vary. The average life expectancy after diagnosis has been reported to be between 8 and 10 years but may range from 3 to 20 years. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – AD should be suspected in any older adult with insidious onset, progressive decline in memory, and at least one other cognitive domain leading to impaired functioning. The diagnosis of AD is made in large part by this clinical assessment. (See <a class="local">'Clinical assessment'</a> above.)</p><p></p><p class="bulletIndent1">Neuropsychologic testing may provide confirmatory information and aid in patient management. A neuroimaging study should be obtained on every patient suspected of having AD. (See <a class="local">'Role of neuropsychologic testing'</a> above and <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">In selected cases (eg, those with young age of onset or atypical presentations), other imaging or biomarker tests including 18-F fluorodeoxyglucose positron emission tomography (FDG-PET), cerebrospinal fluid (CSF) testing, or amyloid/tau PET may be helpful, although access and reimbursement for these tests may present challenges. If use of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> is being considered, confirmation of amyloid status is necessary with either amyloid PET or CSF testing. (See <a class="local">'Neuroimaging'</a> above and <a class="local">'Role of biomarkers'</a> above.)</p><p></p><p class="headingAnchor" id="H186650738"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas Grabowski, Jr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011; 377:1019.</a></li><li><a class="nounderline abstract_t">Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351.</a></li><li><a class="nounderline abstract_t">Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 2014; 83:253.</a></li><li><a class="nounderline abstract_t">Schupf N, Kapell D, Nightingale B, et al. Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 1998; 50:991.</a></li><li><a class="nounderline abstract_t">Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet 2012; 380:1429.</a></li><li><a class="nounderline abstract_t">Mortamais M, Ash JA, Harrison J, et al. Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimers Dement 2017; 13:468.</a></li><li><a class="nounderline abstract_t">Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 1957; 20:11.</a></li><li><a class="nounderline abstract_t">Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: Enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986; 6:2950.</a></li><li><a class="nounderline abstract_t">Peters F, Collette F, Degueldre C, et al. The neural correlates of verbal short-term memory in Alzheimer's disease: An fMRI study. Brain 2009; 132:1833.</a></li><li><a class="nounderline abstract_t">Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012; 78:379.</a></li><li><a class="nounderline abstract_t">Ahmed S, Mitchell J, Arnold R, et al. Memory complaints in mild cognitive impairment, worried well, and semantic dementia patients. Alzheimer Dis Assoc Disord 2008; 22:227.</a></li><li><a class="nounderline abstract_t">McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Stokholm J, Vogel A, Gade A, Waldemar G. Heterogeneity in executive impairment in patients with very mild Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 22:54.</a></li><li><a class="nounderline abstract_t">Harwood DG, Sultzer DL, Feil D, et al. Frontal lobe hypometabolism and impaired insight in Alzheimer disease. Am J Geriatr Psychiatry 2005; 13:934.</a></li><li><a class="nounderline abstract_t">Barrett AM, Eslinger PJ, Ballentine NH, Heilman KM. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology 2005; 64:693.</a></li><li><a class="nounderline abstract_t">McDaniel KD, Edland SD, Heyman A. Relationship between level of insight and severity of dementia in Alzheimer disease. CERAD Clinical Investigators. Consortium to Establish a Registry for Alzheimer's Disease. Alzheimer Dis Assoc Disord 1995; 9:101.</a></li><li><a class="nounderline abstract_t">Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: Association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:83.</a></li><li><a class="nounderline abstract_t">Mizrahi R, Starkstein SE, Jorge R, Robinson RG. Phenomenology and clinical correlates of delusions in Alzheimer disease. Am J Geriatr Psychiatry 2006; 14:573.</a></li><li><a class="nounderline abstract_t">Parakh R, Roy E, Koo E, Black S. Pantomime and imitation of limb gestures in relation to the severity of Alzheimer's disease. Brain Cogn 2004; 55:272.</a></li><li><a class="nounderline abstract_t">Kato M, Meguro K, Sato M, et al. Ideomotor apraxia in patients with Alzheimer disease: Why do they use their body parts as objects? Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:45.</a></li><li><a class="nounderline abstract_t">Giannakopoulos P, Duc M, Gold G, et al. Pathologic correlates of apraxia in Alzheimer disease. Arch Neurol 1998; 55:689.</a></li><li><a class="nounderline abstract_t">Sarazin M, Stern Y, Berr C, et al. Neuropsychological predictors of dependency in patients with Alzheimer disease. Neurology 2005; 64:1027.</a></li><li><a class="nounderline abstract_t">Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer's disease and Parkinson's disease on olfaction: A meta-analysis. Behav Brain Res 2012; 231:60.</a></li><li><a class="nounderline abstract_t">Sun GH, Raji CA, Maceachern MP, Burke JF. Olfactory identification testing as a predictor of the development of Alzheimer's dementia: A systematic review. Laryngoscope 2012; 122:1455.</a></li><li><a class="nounderline abstract_t">Bahar-Fuchs A, Moss S, Rowe C, Savage G. Olfactory performance in AD, aMCI, and healthy ageing: A unirhinal approach. Chem Senses 2010; 35:855.</a></li><li><a class="nounderline abstract_t">Stamps JJ, Bartoshuk LM, Heilman KM. A brief olfactory test for Alzheimer's disease. J Neurol Sci 2013; 333:19.</a></li><li><a class="nounderline abstract_t">Quarmley M, Moberg PJ, Mechanic-Hamilton D, et al. Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease. J Alzheimers Dis 2017; 55:1497.</a></li><li><a class="nounderline abstract_t">Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--A bidirectional relationship. Nat Rev Neurol 2014; 10:115.</a></li><li><a class="nounderline abstract_t">Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013; 70:587.</a></li><li><a class="nounderline abstract_t">Spira AP, Gamaldo AA, An Y, et al. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol 2013; 70:1537.</a></li><li><a class="nounderline abstract_t">Brown BM, Rainey-Smith SR, Villemagne VL, et al. The relationship between sleep quality and brain amyloid burden. Sleep 2016; 39:1063.</a></li><li><a class="nounderline abstract_t">Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986; 36:1226.</a></li><li><a class="nounderline abstract_t">McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992; 33:657.</a></li><li><a class="nounderline abstract_t">Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990; 47:847.</a></li><li><a class="nounderline abstract_t">Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: Who, when, and how common? Arch Neurol 2009; 66:992.</a></li><li><a class="nounderline abstract_t">Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69:368.</a></li><li><a class="nounderline abstract_t">Zarea A, Charbonnier C, Rovelet-Lecrux A, et al. Seizures in dominantly inherited Alzheimer disease. Neurology 2016; 87:912.</a></li><li><a class="nounderline abstract_t">Vossel KA, Tartaglia MC, Nygaard HB, et al. Epileptic activity in Alzheimer's disease: Causes and clinical relevance. Lancet Neurol 2017; 16:311.</a></li><li><a class="nounderline abstract_t">Portet F, Scarmeas N, Cosentino S, et al. Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol 2009; 66:1120.</a></li><li><a class="nounderline abstract_t">McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939.</a></li><li><a class="nounderline abstract_t">Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000; 123 Pt 3:484.</a></li><li><a class="nounderline abstract_t">Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130:2636.</a></li><li><a class="nounderline abstract_t">Harasty JA, Halliday GM, Xuereb J, et al. Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology 2001; 56:944.</a></li><li><a class="nounderline abstract_t">Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 2007; 64:1140.</a></li><li><a class="nounderline abstract_t">Bokde AL, Pietrini P, Ibáñez V, et al. The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease. Arch Neurol 2001; 58:480.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study. Lancet Neurol 2012; 11:868.</a></li><li><a class="nounderline abstract_t">Ridgway GR, Lehmann M, Barnes J, et al. Early-onset Alzheimer disease clinical variants: Multivariate analyses of cortical thickness. Neurology 2012; 79:80.</a></li><li><a class="nounderline abstract_t">Balasa M, Gelpi E, Antonell A, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011; 76:1720.</a></li><li><a class="nounderline abstract_t">van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: The case of the missing APOE ɛ4 allele. Lancet Neurol 2011; 10:280.</a></li><li><a class="nounderline abstract_t">Mendez MF, Mendez MA, Martin R, et al. Complex visual disturbances in Alzheimer's disease. Neurology 1990; 40:439.</a></li><li><a class="nounderline abstract_t">Cogan DG. Visual disturbances with focal progressive dementing disease. Am J Ophthalmol 1985; 100:68.</a></li><li><a class="nounderline abstract_t">Hof PR, Bouras C, Constantinidis J, Morrison JH. Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome. J Neuropathol Exp Neurol 1990; 49:168.</a></li><li><a class="nounderline abstract_t">Levine DN, Lee JM, Fisher CM. The visual variant of Alzheimer's disease: A clinicopathologic case study. Neurology 1993; 43:305.</a></li><li><a class="nounderline abstract_t">Renner JA, Burns JM, Hou CE, et al. Progressive posterior cortical dysfunction: A clinicopathologic series. Neurology 2004; 63:1175.</a></li><li><a class="nounderline abstract_t">Andrade K, Kas A, Valabrègue R, et al. Visuospatial deficits in posterior cortical atrophy: Structural and functional correlates. J Neurol Neurosurg Psychiatry 2012; 83:860.</a></li><li><a class="nounderline abstract_t">Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement 2017; 13:870.</a></li><li><a class="nounderline abstract_t">Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: Early age at onset AD spectrum. Neurology 2009; 73:1571.</a></li><li><a class="nounderline abstract_t">Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63:1168.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Jack CR Jr, Kantarci K, et al. Imaging correlates of posterior cortical atrophy. Neurobiol Aging 2007; 28:1051.</a></li><li><a class="nounderline abstract_t">Ross SJ, Graham N, Stuart-Green L, et al. Progressive biparietal atrophy: An atypical presentation of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61:388.</a></li><li><a class="nounderline abstract_t">Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012; 11:170.</a></li><li><a class="nounderline abstract_t">Caroppo P, Belin C, Grabli D, et al. Posterior cortical atrophy as an extreme phenotype of GRN mutations. JAMA Neurol 2015; 72:224.</a></li><li><a class="nounderline abstract_t">Mitchell SB, Lucente D, Larvie M, et al. A 63-year-old man with progressive visual symptoms. JAMA Neurol 2017; 74:114.</a></li><li><a class="nounderline abstract_t">Josephs KA, Whitwell JL, Duffy JR, et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 2008; 70:25.</a></li><li><a class="nounderline abstract_t">Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59:156.</a></li><li><a class="nounderline abstract_t">Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63:709.</a></li><li><a class="nounderline abstract_t">Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55:335.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64:388.</a></li><li><a class="nounderline abstract_t">Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010; 74:42.</a></li><li><a class="nounderline abstract_t">Hu WT, McMillan C, Libon D, et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 2010; 75:595.</a></li><li><a class="nounderline abstract_t">Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006.</a></li><li><a class="nounderline abstract_t">Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Ann Neurol 2018; 84:729.</a></li><li><a class="nounderline abstract_t">Mesulam MM, Dickerson BC, Sherman JC, et al. Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language. N Engl J Med 2017; 376:158.</a></li><li><a class="nounderline abstract_t">Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011; 82:45.</a></li><li><a class="nounderline abstract_t">Blennerhassett R, Lillo P, Halliday GM, et al. Distribution of pathology in frontal variant Alzheimer's disease. J Alzheimers Dis 2014; 39:63.</a></li><li><a class="nounderline abstract_t">Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51:888.</a></li><li><a class="nounderline abstract_t">Arvanitakis Z, Capuano AW, Leurgans SE, et al. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol 2016; 15:934.</a></li><li><a class="nounderline abstract_t">Schneider JA, Arvanitakis Z, Yu L, et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012; 135:3005.</a></li><li><a class="nounderline abstract_t">Nag S, Yu L, Capuano AW, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 2015; 77:942.</a></li><li><a class="nounderline abstract_t">Connor DJ, Salmon DP, Sandy TJ, et al. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998; 55:994.</a></li><li><a class="nounderline abstract_t">Weiner MF, Hynan LS, Parikh B, et al. Can Alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J Geriatr Psychiatry Neurol 2003; 16:245.</a></li><li><a class="nounderline abstract_t">Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586.</a></li><li><a class="nounderline abstract_t">Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999; 56:857.</a></li><li><a class="nounderline abstract_t">Adak S, Illouz K, Gorman W, et al. Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology 2004; 63:108.</a></li><li><a class="nounderline abstract_t">Nourhashémi F, Ousset PJ, Gillette-Guyonnet S, et al. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). Int J Geriatr Psychiatry 2008; 23:460.</a></li><li><a class="nounderline abstract_t">Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr 2000; 12:231.</a></li><li><a class="nounderline abstract_t">Schmidt C, Wolff M, Weitz M, et al. Rapidly progressive Alzheimer disease. Arch Neurol 2011; 68:1124.</a></li><li><a class="nounderline abstract_t">Bernick C, Cummings J, Raman R, et al. Age and rate of cognitive decline in Alzheimer disease: Implications for clinical trials. Arch Neurol 2012; 69:901.</a></li><li><a class="nounderline abstract_t">Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry 2015; 172:460.</a></li><li><a class="nounderline abstract_t">Helzner EP, Scarmeas N, Cosentino S, et al. Survival in Alzheimer disease: A multiethnic, population-based study of incident cases. Neurology 2008; 71:1489.</a></li><li><a class="nounderline abstract_t">Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140:501.</a></li><li><a class="nounderline abstract_t">Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344:1111.</a></li><li><a class="nounderline abstract_t">Rountree SD, Chan W, Pavlik VN, et al. Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther 2012; 4:16.</a></li><li><a class="nounderline abstract_t">Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.</a></li><li><a class="nounderline abstract_t">Davis DH, Creavin ST, Yip JL, et al. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. Cochrane Database Syst Rev 2015; :CD010775.</a></li><li><a class="nounderline abstract_t">Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011; 77:1272.</a></li><li><a class="nounderline abstract_t">Shaughnessy L, Sheard S, Goldfarb D, Atri A. Cognitive assessment of Alzheimer's disease and dementias in clinical practice: Pragmatics of brief instruments and neuropsychological evaluation. J Clin Psychiatry 2019; 80.</a></li><li><a class="nounderline abstract_t">Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143.</a></li><li><a class="nounderline abstract_t">van de Pol LA, Hensel A, Barkhof F, et al. Hippocampal atrophy in Alzheimer disease: Age matters. Neurology 2006; 66:236.</a></li><li><a class="nounderline abstract_t">Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old. Neurology 2007; 69:1521.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study. Neurology 2008; 71:743.</a></li><li><a class="nounderline abstract_t">Kantarci K, Avula R, Senjem ML, et al. Dementia with Lewy bodies and Alzheimer disease: Neurodegenerative patterns characterized by DTI. Neurology 2010; 74:1814.</a></li><li><a class="nounderline abstract_t">Raji CA, Lopez OL, Kuller LH, et al. Age, Alzheimer disease, and brain structure. Neurology 2009; 73:1899.</a></li><li><a class="nounderline abstract_t">Wahlund LO, Almkvist O, Blennow K, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging 2005; 16:427.</a></li><li><a class="nounderline abstract_t">Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012; 78:84.</a></li><li><a class="nounderline abstract_t">McEvoy LK, Holland D, Hagler DJ Jr, et al. Mild cognitive impairment: Baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology 2011; 259:834.</a></li><li><a class="nounderline abstract_t">Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85.</a></li><li><a class="nounderline abstract_t">Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286:2120.</a></li><li><a class="nounderline abstract_t">Powers WJ, Perlmutter JS, Videen TO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992; 42:765.</a></li><li><a class="nounderline abstract_t">Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; 36:879.</a></li><li><a class="nounderline abstract_t">O'Brien JL, O'Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74:1969.</a></li><li><a class="nounderline abstract_t">Hu WT, Wang Z, Lee VM, et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010; 75:881.</a></li><li><a class="nounderline abstract_t">Pickut BA, Saerens J, Mariën P, et al. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. J Nucl Med 1997; 38:929.</a></li><li><a class="nounderline abstract_t">Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39:1875.</a></li><li><a class="nounderline abstract_t">Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130:2616.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034.</a></li><li><a class="nounderline abstract_t">Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004; 3:519.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68:1205.</a></li><li><a class="nounderline abstract_t">Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 2007; 68:501.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665.</a></li><li><a class="nounderline abstract_t">Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 2008; 7:129.</a></li><li><a class="nounderline abstract_t">Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7:161.</a></li><li><a class="nounderline abstract_t">Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: A case-control study. Neurology 2010; 75:111.</a></li><li><a class="nounderline abstract_t">Roe CM, Mintun MA, Ghoshal N, et al. Alzheimer disease identification using amyloid imaging and reserve variables: Proof of concept. Neurology 2010; 75:42.</a></li><li><a class="nounderline abstract_t">Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010; 68:319.</a></li><li><a class="nounderline abstract_t">Tolboom N, van der Flier WM, Boverhoff J, et al. Molecular imaging in the diagnosis of Alzheimer's disease: Visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010; 81:882.</a></li><li><a class="nounderline abstract_t">Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275.</a></li><li><a class="nounderline abstract_t">Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10:424.</a></li><li><a class="nounderline abstract_t">Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68:1398.</a></li><li><a class="nounderline abstract_t">Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68:1404.</a></li><li><a class="nounderline abstract_t">Wolk DA, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer's disease: Comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012; 83:923.</a></li><li><a class="nounderline abstract_t">Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol 2012; 11:669.</a></li><li><a class="nounderline abstract_t">Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 2012; 79:1636.</a></li><li><a class="nounderline abstract_t">Lim YY, Ellis KA, Pietrzak RH, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012; 79:1645.</a></li><li><a class="nounderline abstract_t">Niedowicz DM, Beckett TL, Matveev S, et al. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol 2012; 72:564.</a></li><li><a class="nounderline abstract_t">Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630.</a></li><li><a class="nounderline abstract_t">Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. JAMA 2015; 313:1939.</a></li><li><a class="nounderline abstract_t">Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 2015; 313:1924.</a></li><li><a class="nounderline abstract_t">Boccardi M, Altomare D, Ferrari C, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study. JAMA Neurol 2016; 73:1417.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Gatsonis C, Apgar C, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 2019; 321:1286.</a></li><li><a class="nounderline abstract_t">Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med 2012; 367:885.</a></li><li class="breakAll">Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on December 11, 2020).</li><li><a class="nounderline abstract_t">Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013; 54:476.</a></li><li><a class="nounderline abstract_t">Cummings J, Salloway S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 2022; 18:531.</a></li><li><a class="nounderline abstract_t">Xia C, Makaretz SJ, Caso C, et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol 2017; 74:427.</a></li><li><a class="nounderline abstract_t">Villemagne VL, Okamura N, Rowe CC. Untangling tau imaging. Alzheimers Dement (Amst) 2016; 4:39.</a></li><li><a class="nounderline abstract_t">Fleisher AS, Pontecorvo MJ, Devous MD Sr, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol 2020; 77:829.</a></li><li><a class="nounderline abstract_t">Ghirelli A, Tosakulwong N, Weigand SD, et al. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. Ann Neurol 2020; 88:1009.</a></li><li><a class="nounderline abstract_t">Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 2010; 9:1118.</a></li><li><a class="nounderline abstract_t">Wolk DA, Sadowsky C, Safirstein B, et al. Use of flutemetamol F 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment. JAMA Neurol 2018; 75:1114.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14:535.</a></li><li><a class="nounderline abstract_t">Galasko D. Cerebrospinal fluid biomarkers in Alzheimer disease: A fractional improvement? Arch Neurol 2003; 60:1195.</a></li><li><a class="nounderline abstract_t">Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 2007; 68:666.</a></li><li><a class="nounderline abstract_t">Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007; 69:1006.</a></li><li><a class="nounderline abstract_t">Sonnen JA, Montine KS, Quinn JF, et al. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008; 7:704.</a></li><li><a class="nounderline abstract_t">Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795.</a></li><li><a class="nounderline abstract_t">Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012; 69:1318.</a></li><li><a class="nounderline abstract_t">Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 2015; 77:301.</a></li><li><a class="nounderline abstract_t">Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. Lancet Neurol 2016; 15:673.</a></li><li><a class="nounderline abstract_t">Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020; 19:422.</a></li><li><a class="nounderline abstract_t">Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 2020; 324:772.</a></li><li><a class="nounderline abstract_t">Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain 2020; 143:3234.</a></li><li><a class="nounderline abstract_t">Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 93:e1647.</a></li><li><a class="nounderline abstract_t">Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338:506.</a></li><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.</a></li><li><a class="nounderline abstract_t">Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239.</a></li><li><a class="nounderline abstract_t">Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18:S1.</a></li><li><a class="nounderline abstract_t">Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Phung TK, Andersen BB, Høgh P, et al. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007; 24:220.</a></li><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56:303.</a></li><li><a class="nounderline abstract_t">Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996; 46:661.</a></li><li><a class="nounderline abstract_t">Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270.</a></li><li><a class="nounderline abstract_t">Vos SJ, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 2015; 138:1327.</a></li><li><a class="nounderline abstract_t">Wolk D, Salloway S, Dickerson B. Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. JAMA 2019; 321:2289.</a></li><li><a class="nounderline abstract_t">Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 2014; 13:614.</a></li><li><a class="nounderline abstract_t">Morris JC, Blennow K, Froelich L, et al. Harmonized diagnostic criteria for Alzheimer's disease: Recommendations. J Intern Med 2014; 275:204.</a></li><li><a class="nounderline abstract_t">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280.</a></li></ol></div><div id="topicVersionRevision">Topic 5071 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371747" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330961" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Frequency of stages of Alzheimer-related lesions in different age categories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928124" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566384" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Earlier onset of Alzheimer's disease in men with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Amnesic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27702618" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13406589" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Loss of recent memory after bilateral hippocampal lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760943" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433442" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238414" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580592" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Memory complaints in mild cognitive impairment, worried well, and semantic dementia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514250" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514250" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682794" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Heterogeneity in executive impairment in patients with very mild Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286436" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Frontal lobe hypometabolism and impaired insight in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728294" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7662321" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Relationship between level of insight and severity of dementia in Alzheimer disease. CERAD Clinical Investigators. Consortium to Establish a Registry for Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780626" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816010" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phenomenology and clinical correlates of delusions in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15177793" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pantomime and imitation of limb gestures in relation to the severity of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234908" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ideomotor apraxia in patients with Alzheimer disease: why do they use their body parts as objects?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605726" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathologic correlates of apraxia in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781821" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neuropsychological predictors of dependency in patients with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414849" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22552846" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Olfactory identification testing as a predictor of the development of Alzheimer's dementia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870956" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Olfactory performance in AD, aMCI, and healthy ageing: a unirhinal approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927938" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A brief olfactory test for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27886011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366271" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sleep and Alzheimer disease pathology--a bidirectional relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23479184" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sleep quality and preclinical Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145859" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Self-reported sleep andβ-amyloid deposition in community-dwelling older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091528" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Relationship between Sleep Quality and Brain Amyloid Burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3092131" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Seizures and myoclonus in patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1628580" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epileptic seizures in elderly patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375689" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Advanced Alzheimer's disease is a risk factor for late-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667221" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Seizures in Alzheimer disease: who, when, and how common?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410444" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Incidence of new-onset seizures in mild to moderate Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27466472" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Seizures in dominantly inherited Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327340" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epileptic activity in Alzheimer's disease: causes and clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752301" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6610841" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686172" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898010" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Focal cortical presentations of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294934" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cortical degeneration associated with phonologic and semantic language impairments in AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698704" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255453" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951070" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722624" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early-onset Alzheimer disease clinical variants: multivariate analyses of cortical thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576687" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185234" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Early-onset versus late-onset Alzheimer's disease: the case of the missing APOEɛ4 allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2314585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Complex visual disturbances in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893141" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Visual disturbances with focal progressive dementing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307982" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437694" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The visual variant of Alzheimer's disease: a clinicopathologic case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477534" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Progressive posterior cortical dysfunction: a clinicopathologic series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22645257" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Visuospatial deficits in posterior cortical atrophy: structural and functional correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28259709" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Consensus classification of posterior cortical atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901249" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477533" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797786" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Imaging correlates of posterior cortical atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890778" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265212" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Posterior cortical atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25546130" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Posterior cortical atrophy as an extreme phenotype of GRN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27842190" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A 63-Year-Old Man With Progressive Visual Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166704" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374817" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical and pathological characterization of progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412267" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991811" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cognition and anatomy in three variants of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18991338" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940270" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prediction of pathology in primary progressive language and speech disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713948" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325651" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Classification of primary progressive aphasia and its variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255971" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence of amyloid-βpathology in distinct variants of primary progressive aphasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076711" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562467" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121962" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Distribution of pathology in frontal variant Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080388" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical-neuropathological correlations in Alzheimer's disease and related dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27312738" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23065790" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707479" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678318" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14653435" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771246" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404988" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249619" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predicting the rate of cognitive decline in aging and early Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894422" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10937543" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911694" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rapidly progressive Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431834" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25585033" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981370" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068977" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Survival after initial diagnosis of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297701" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A reevaluation of the duration of survival after the onset of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594761" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Factors that influence survival in a probable Alzheimer disease cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817019" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513331" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917776" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31237995" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cognitive Assessment of Alzheimer's Disease and Dementias in Clinical Practice: Pragmatics of Brief Instruments and Neuropsychological Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342678" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434661" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hippocampal atrophy in Alzheimer disease: age matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923614" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765650" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513818" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846828" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Age, Alzheimer disease, and brain structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088692" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22189451" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471273" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9225689" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694153" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565229" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487046" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Positron emission tomography in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463288" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20819999" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Distinct cerebral perfusion patterns in FTLD and AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189144" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9829574" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cerebral glucose metabolism in patients with frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704526" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22131541" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15324720" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : PET imaging of amyloid in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420404" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065593" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263627" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191617" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207114" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Current and future uses of neuroimaging for cognitively impaired patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534887" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20603484" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20687209" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543188" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245183" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Use of florbetapir-PET for imaging beta-amyloid pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21481640" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Cerebral amyloid-βPET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747004" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747008" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791901" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749065" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-βplaques: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786606" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Amyloid-βassessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071163" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109151" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339640" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988463" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988462" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27802513" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30938796" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931256" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Brain amyloid imaging--FDA approval of florbetapir F18 injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931256" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Brain amyloid imaging--FDA approval of florbetapir F18 injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359661" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34314093" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Aducanumab: Appropriate use recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241163" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489878" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Untangling tau imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338734" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32869362" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Sensitivity-Specificity of Tau and AmyloidβPositron Emission Tomography in Frontotemporal Lobar Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934914" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Revising the definition of Alzheimer's disease: a new lexicon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799984" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653606" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975282" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325273" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785669" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Longitudinal changes of CSF biomarkers in memory clinic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635019" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Biomarkers for cognitive impairment and dementia in elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784036" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801742" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Blood-based protein biomarkers for diagnosis of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25469919" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Plasma levels of apolipoprotein E and risk of dementia in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27068280" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333900" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32722745" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33068398" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31371569" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : High-precision plasmaβ-amyloid 42/40 predicts current and future brain amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468467" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646655" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1759558" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Neuropathological stageing of Alzheimer-related changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330978" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864910" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Diagnosis of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864910" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Diagnosis of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690555" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Validity of dementia diagnoses in the Danish hospital registers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190820" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Mild cognitive impairment: clinical characterization and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618663" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514249" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693589" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211328" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24849862" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24605805" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Harmonized diagnostic criteria for Alzheimer's disease: recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514248" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
